. 2017 Sep 12;89(11):1107–1116. doi: 10.1212/WNL.0000000000004313
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Table 1.
AEs through year 5 of the extension in patients treated with alemtuzumab 12 mg
